Since the beginning of 2026, the field of gastric cancer treatment has witnessed a major breakthrough. China’s National Medical Products Administration (NMPA) approved Retlirafusp Alfa Injection (SHR-1701) for first-line treatment of PD-L1-positive advanced gastric cancer…
From emergency medicines to chronic disease treatments, from anti-infectives to oncology therapies, instability in the global pharmaceutical supply chain is increasingly affecting healthcare systems worldwide. Between 2023 and 2025, drug shortages by country have worsened…
Immune checkpoint inhibitors (ICIs) restore T-cell–mediated antitumor immunity by blocking key regulatory pathways such as PD-1/PD-L1 and CTLA-4, and have become a cornerstone of modern oncology treatment. As one of the world’s most important markets…
Neuroscience (CNS) has long been regarded as one of the most challenging areas in the pharmaceutical industry, due to long development timelines, high failure rates, and complex disease mechanisms. ✨ In recent years, breakthroughs in…
To further improve the standardization of diagnosis and treatment for primary liver cancer, the newly released 2026 guideline introduces important HCC first- and second-line treatment updates, particularly in systemic therapy. The Medical Administration Department of…
Over the past decade, autoimmune diseases have remained one of the most stable and high-growth areas in global drug innovation. From TNF-α inhibitors to IL-17/IL-23 biologics and the rise of JAK inhibitors, the field has…
China’s pharmaceutical industry is undergoing a profound structural transformation, and China pharmaceutical export trends are also changing significantly. From a past dominated by active pharmaceutical ingredient (API) exports to today’s expansion into high-end formulations, innovative…
Breast cancer is the most common malignancy among women worldwide, with incidence continuing to rise. Precision molecular subtyping and individualized therapies have improved outcomes, but tumor heterogeneity, antigen escape, and drug resistance remain major challenges.…
The landscape of approved cell and gene therapy drugs in China is rapidly evolving, as these advanced treatment approaches are increasingly recognized worldwide for their revolutionary potential in treating cancer, genetic disorders, and rare diseases.…
Currently, africa pharmaceutical industry challenges are increasingly recognized as a key issue in the global healthcare supply system. These challenges extend beyond drug access and also involve quality assurance, supply stability, and cross-border distribution efficiency.…
With the continuous restructuring of the global healthcare supply chain, China has become one of the most important sources of international pharmaceutical procurement. An increasing number of healthcare institutions, pharmaceutical distributors, research organizations, and medical…
In the context of continuous development of global healthcare systems, drug accessibility has become a critical factor influencing patient outcomes. Despite the rapid emergence of innovative therapies, high costs, complex cross-border distribution, and strict regulatory…
